Director's Resignation May Prompt FDA Criminal Investigations Overhaul
This article was originally published in The Tan Sheet
Executive Summary
The resignation of Terry Vermillion, the long-time head of FDA's Office of Criminal Investigations, will give the agency a chance to overhaul thoroughly the office.
You may also be interested in...
Better Intra-Agency Reviews Could Speed FDA Seizure, Injunction Decisions
FDA is working to expedite its decision-making process for seizures and injunctions, which could translate into quicker enforcement actions for violative products.
FDA Agrees With GAO Recommendations To Give Prosecutions Higher Priority
FDA's plans to increase prosecutions of noncompliant food and drug industry officials, as recommended by an internal committee, should include the dietary supplement market, stakeholders say
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.